{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:07:01Z","timestamp":1753891621407,"version":"3.41.2"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background and purpose<\/jats:title><jats:p>Myasthenia gravis (MG) is characterized by fluctuating muscle weakness due to immune-mediated damage to acetylcholine receptors. Viral infections can exacerbate symptoms of muscle weakness, and the clinical status of patients with MG may influence the outcomes of such infections. Here, we identified factors of symptom exacerbation, severe SARS-CoV-2 infection, and pneumonia in patients with MG who are infected with SARS-CoV-2.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The clinical characteristics and outcomes of 341 MG patients infected with SARS-CoV-2 across multiple regions in China were determined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median age of the patients was 49\u202fyears (range: 35\u201360\u202fyears) and the median disease duration was 4\u202fyears (range: 2\u20138\u202fyears). Among the patients, 67 (49.0%) were male and 174 (51.0%) were female. Multivariate analysis indicated that thymectomy [OR, 1.654 (95% CI, 1.036\u20132.643); <jats:italic>p<\/jats:italic>\u202f=\u202f0.035], severe SARS-CoV-2 infection [OR, 4.275 (95% CI, 2.206\u20138.286); <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001], and pyridostigmine bromide [OR, 1.955 (95% CI, 1.192\u20133.206); <jats:italic>p<\/jats:italic>\u202f=\u202f0.008] were associated with exacerbation of MG symptoms in patients infected with SARS-CoV-2. Age was significantly associated with severe SARS-CoV-2 infection [OR, 1.023 (95% CI, 1.001\u20131.046); <jats:italic>p<\/jats:italic>\u202f=\u202f0.008], while patients with cardiac\/vascular comorbidities exhibited an increased likelihood of severe SARS-CoV-2 infection [OR, 3.276 (95% CI, 1.027\u201310.449); <jats:italic>p<\/jats:italic>\u202f=\u202f0.045]. Likewise, steroid treatment [OR, 6.140 (95% CI, 2.335\u201316.140); <jats:italic>p<\/jats:italic>\u202f&amp;lt;\u202f0.001] was associated with a significantly increased likelihood of severe SARS-CoV-2 infection compared with symptomatic treatment. Additionally, gender [OR, 0.323 (95% CI, 0.120\u20130.868); <jats:italic>p<\/jats:italic>\u202f=\u202f0.025] and SARS-CoV-2 severity [OR, 6.067 (95% CI, 1.953\u201318.850); <jats:italic>p<\/jats:italic>\u202f=\u202f0.002] were associated with the occurrence of pneumonia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We identified factors that were associated with the exacerbation of MG symptoms in patients infected with SARS-CoV-2, including thymectomy, severe SARS-CoV-2 infection, and the use of pyridostigmine bromide. Due to the retrospective nature of the study, these findings should be interpreted as associations rather than predictive factors. However, the results confirm the established relationships between severe SARS-CoV-2 infection and age, cardiovascular comorbidities, and the use of steroid treatment, suggesting that these factors should be considered when managing MG patients during SARS-CoV-2 infection.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1482932","type":"journal-article","created":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T05:11:06Z","timestamp":1733893866000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of SARS-CoV-2 infection on patients with myasthenia gravis: a retrospective study in a Chinese population"],"prefix":"10.3389","volume":"15","author":[{"given":"Peng","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengna","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huimin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoyan","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient's perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","article-title":"Myasthenia gravis: a clinical-immunological update","volume":"263","author":"Binks","year":"2016","journal-title":"J Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/14737175.2018.1491310","article-title":"Advances in autoimmune myasthenia gravis management","volume":"18","author":"Wang","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S1474-4422(20)30413-0","article-title":"COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)","volume":"19","author":"Muppidi","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.26689","article-title":"Factors associated with acute exacerbations of myasthenia gravis","volume":"60","author":"Gummi","year":"2019","journal-title":"Muscle Nerve"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.autrev.2012.12.005","article-title":"Infectome: a platform to trace infectious triggers of autoimmunity","volume":"12","author":"Bogdanos","year":"2013","journal-title":"Autoimmun Rev"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41584-024-01167-9","article-title":"Epstein-Barr virus as a potentiator of autoimmune diseases","volume":"20","author":"Robinson","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"95432","DOI":"10.18632\/oncotarget.20731","article-title":"Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?","volume":"8","author":"Cavalcante","year":"2017","journal-title":"Oncotarget"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jhep.2018.01.040","article-title":"Association of hepatitis E virus infection and myasthenia gravis: a pilot study","volume":"68","author":"Wang","year":"2018","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2018.09.015","article-title":"West Nile virus induces a post-infectious pro-inflammatory state that explains transformation of stable ocular myasthenia gravis to myasthenic crises","volume":"395","author":"Hawkes","year":"2018","journal-title":"J Neurol Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3389\/fmed.2020.00164","article-title":"Tumor necrosis factor-alpha signaling may contribute to chronic West Nile virus post-infectious Proinflammatory state","volume":"7","author":"Leis","year":"2020","journal-title":"Front Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1111\/all.14289","article-title":"Eleven faces of coronavirus disease 2019","volume":"75","author":"Dong","year":"2020","journal-title":"Allergy"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.3390\/vaccines10121982","article-title":"The effect of long COVID-19 infection and vaccination on male fertility; a narrative review","volume":"10","author":"Pourmasumi","year":"2022","journal-title":"Vaccine"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1007\/s10072-022-05922-2","article-title":"Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab","volume":"43","author":"Mimori","year":"2022","journal-title":"Neurol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3389\/fneur.2020.01053","article-title":"Myasthenia gravis and COVID-19: clinical characteristics and outcomes","volume":"11","author":"Camelo-Filho","year":"2020","journal-title":"Front Neurol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"106488","DOI":"10.1016\/j.clineuro.2021.106488","article-title":"Impact of COVID-19 pandemic and lockdown in a cohort of myasthenia gravis patients in India","volume":"202","author":"Kalita","year":"2021","journal-title":"Clin Neurol Neurosurg"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12883-022-02564-x","article-title":"Impact of COVID-19 infection among myasthenia gravis patients- a Cerner real-world data (TM) study","volume":"22","author":"Digala","year":"2022","journal-title":"BMC Neurol"},{"key":"ref19","first-page":"1","article-title":"Guidelines for the diagnosis and treatment of myasthenia gravis in China","volume":"28","author":"Chang","year":"2021","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"595068","DOI":"10.3389\/fimmu.2020.595068","article-title":"Case report: orbital myositis and myasthenia gravis as symptoms of immune reconstitution inflammatory syndrome in a patient with human immunodeficiency virus infection","volume":"11","author":"Wang","year":"2020","journal-title":"Front Immunol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00415-022-11472-6","article-title":"New-onset myasthenia gravis after SARS-CoV-2 infection: case report and literature review","volume":"270","author":"Tereshko","year":"2023","journal-title":"J Neurol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1111\/ene.15158","article-title":"Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival","volume":"29","author":"Jakubikova","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1111\/j.1749-6632.1981.tb33766.x","article-title":"Observations of the natural history of myasthenia gravis and the effect of thymectomy","volume":"377","author":"Oosterhuis","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/icvts\/ivt510","article-title":"Is thymectomy in non-thymomatous myasthenia gravis of any benefit?","volume":"18","author":"Diaz","year":"2014","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2302892","article-title":"Health consequences of Thymus removal in adults","volume":"389","author":"Kooshesh","year":"2023","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2300796","DOI":"10.1183\/13993003.00796-2023","article-title":"Age, host response, and mortality in COVID-19","volume":"62","author":"Veiga","year":"2023","journal-title":"Eur Respir J"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","article-title":"Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis","volume":"94","author":"Yang","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2001227","DOI":"10.1183\/13993003.01227-2020","article-title":"Cardiovascular comorbidity and its impact on patients with COVID-19","volume":"55","author":"Guan","year":"2020","journal-title":"Eur Respir J"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41574-020-0341-0","article-title":"Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment","volume":"16","author":"Chotiyarnwong","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.cmet.2021.01.002","article-title":"The neutrophil-to-lymphocyte ratio determines clinical efficacy of corticosteroid therapy in patients with COVID-19","volume":"33","author":"Cai","year":"2021","journal-title":"Cell Metab"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S0140-6736(20)30920-X","article-title":"SARS-CoV-2 and viral sepsis: observations and hypotheses","volume":"395","author":"Li","year":"2020","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.pediatrneurol.2023.06.008","article-title":"Clinical features, treatment, and prognostic factors of childhood-onset myasthenia gravis in a large Chinese cohort","volume":"146","author":"Bi","year":"2023","journal-title":"Pediatr Neurol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1482932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T05:11:11Z","timestamp":1733893871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1482932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,11]]},"references-count":37,"alternative-id":["10.3389\/fneur.2024.1482932"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1482932","relation":{},"ISSN":["1664-2295"],"issn-type":[{"type":"electronic","value":"1664-2295"}],"subject":[],"published":{"date-parts":[[2024,12,11]]},"article-number":"1482932"}}